Inceptor Bio, a US-based biotechnology company advancing cell therapies for difficult-to-treat cancers, announced on Monday that it has named Dr Matthias Schroff as its new CEO.
The new CEO is also joining the board of directors. He succeeds Shailesh Maingi, who will remain as executive chairman.
Dr Schroff has extensive biopharmaceutical leadership experience. He has served as chief executive officer of Exicure, chief executive officer of Vaximm AG and held several positions on management levels at Mologen, ultimately rising to chief executive officer.
Viatris adds new board director
Bloom Science names new board chair
Prescient Healthcare names new directors
Alcami names new general manager, Biostorage and Pharma Services
Cell Easy Appoints CDMO Expert Dr. Sebastien Ribault as Independent Board Director
Nexus Pharmaceuticals Appoints Two New Board Members
Scorpius BioManufacturing names new vice president, Quality and Regulatory Affairs
NeuroTrauma Sciences names new CMO and EVP of Regulatory Affairs and Quality Assurance